Sling helps restore bladder control after prostatectomy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 10
Volume 16
Issue 10

A 58-year-old prostate cancer patient who developed stress urinary incontinence after successful prostatectomy was the first man at the University of Texas Southwestern Medical Center to receive a new type of sling to prevent leakage, the AdVance Male Sling System, from American Medical Systems, Minnetonka, Minnesota

DALLAS—A 58-year-old prostate cancer patient who developed stress urinary incontinence after successful prostatectomy was the first man at the University of Texas Southwestern Medical Center to receive a new type of sling to prevent leakage, the AdVance Male Sling System, from American Medical Systems, Minnetonka, Minnesota (see Figure).

The device has been available since August 2006, but Allen Morey, MD, was the first to use the device at UT Southwestern. Dr. Morey, professor of urology, joined the UT Southwestern faculty in June as a subspecialist in reconstructive urology.

Although slings have been used for years in women to improve urinary control, they are a relatively new treatment for men, Dr. Morey said. Prior slings were anchored to the pelvis with small bone screws to secure fixation, but that was painful for many patients.

The new device involves passage of a thin strip of mesh between pinpoint incisions on the inner thighs, which is then passed deep beneath the bottom of the urethra to increase support in precisely the area where the tissues are weakened. This additional flow resistance prevents the leakage of urine when abdominal pressure increases.

The procedure is best suited for mild-to-moderate stress urinary incontinence, usually defined as patients who wear one to four pads per day to absorb any leakage.

More than 2 million men worldwide suffer from stress urinary incontinence, and a majority of these men are prostate cancer survivors, having undergone surgery for the treatment of their cancer with the often unavoidable outcome of a damaged urinary sphincter.

"I believe there are many men who have a 'nuisance' level of urinary incontinence after prostate cancer treatment that is bothersome during strenuous activities," Dr. Morey said. "To cope, these men often restrict their activities or limit their fluid intake. We can now offer these men a chance to return to their daily activities with minimal or no pain. They are the ones who would benefit from this low-risk procedure."

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Related Content